Insights

Gathering insights about Kyo…

Similar companies to Kyo

Kyo Tech Stack

Kyo uses 8 technology products and services including TikTok Pixel, Facebook Pixel, Tableau, and more. Explore Kyo's tech stack below.

TikTok Pixel
Analytics
Facebook Pixel
Analytics
Tableau
Business Intelligence
Apple iCloud Mail
Email
Lightbox
Javascript Libraries
Moment.js
Javascript Libraries
Google Sheets
Office Suites
Priority Hints
Performance

Media & News

OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,464,695 shares.
Nov 21, 2025 | www.globenewswire.com
OKYO Pharma to Present at OIS XV in San Diego
LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Gary S. Jacob, Ph.D., Chief Executive Officer, will present at the Ophthalmology Innovation Summit (OIS) XV. The presentation is scheduled for Saturday, November 22, 2025, from 8:30-9:30 AM PT, as part of the "Anterior Innovation Showcase" session.
Nov 18, 2025 | www.globenewswire.com
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 210,000 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,382,677 shares.
Oct 16, 2025 | www.globenewswire.com
OKYO Pharma reports company stock purchase by executive chair
OKYO Pharma Ltd (NASDAQ:OKYO) said it has been informed that Panetta Partners Limited, an entity in which the company’s executive chairman Gabriele Cerrone...
Oct 16, 2025 | www.proactiveinvestors.com
OKYO Pharma maps out registration path with 100-patient trial of Urcosimod for neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) plans to run a 100-patient, multi-centre study of its eye-drop candidate Urcosimod in neuropathic corneal pain, laying out a path it hopes can lead to US approval in a condition with no Food & Drug Administration-approved therapies. The company said the next study will be a multiple-ascending-dose (MAD) trial, researcher-speak for testing several dose levels, run as a randomized, placebo-controlled, double-masked design across several U.S.
Sep 22, 2025 | www.proactiveinvestors.com
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announced plans for the next stage of clinical development for its lead drug candidate, urcosimod, to treat neuropathic corneal pain (NCP).
Sep 22, 2025 | www.globenewswire.com
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company's Phase 2 trial evaluating urcosimod in patients with neuropathic corneal pain. Jacob explained that neuropathic corneal pain is a severe nerve pain condition without any FDA-approved treatments, describing it as “like having a spinal cord injury in your eye.
Jul 19, 2025 | www.proactiveinvestors.com

Kyo's Email Address Formats

Kyo uses at least 2 format(s):

Kyo Email Formats	Example	Percentage
FLast@gatewaylg.com	JDoe@gatewaylg.com	51%
FirstL@gatewaylg.com	JohnD@gatewaylg.com	24%
First@gatewaylg.com	John@gatewaylg.com	20%
FirstLast@gatewaylg.com	JohnDoe@gatewaylg.com	3%
FirstLa@gatewaylg.com	JohnDo@gatewaylg.com	1%
FirstMiddleLa@gatewaylg.com	JohnMichaelDo@gatewaylg.com	1%
First.Last@kyocare.com	John.Doe@kyocare.com	60%
FirstL@kyocare.com	JohnD@kyocare.com	28%
First@kyocare.com	John@kyocare.com	9%
FLast@kyocare.com	JDoe@kyocare.com	3%

Frequently Asked Questions

Where is Kyo's headquarters located?

Kyo's main headquarters is located at 295 89th St Suite 306 Daly City, California 94015 US. The company has employees across 5 continents, including North AmericaAsiaEurope.

What is Kyo's phone number?

You can contact Kyo's main corporate office by phone at

+1-415-513-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Kyo's stock symbol?

Kyo is a publicly traded company; the company's stock symbol is OKYO.

What is Kyo's official website and social media links?

Kyo's official website is kyocare.com and has social profiles on LinkedIn.

What is Kyo's NAICS code?

Kyo's NAICS code is 62133 - Offices of Mental Health Practitioners (except Physicians).

How many employees does Kyo have currently?

As of October 2025, Kyo has approximately 1.1K employees across 5 continents, including North AmericaAsiaEurope. Key team members include Chief Financial Officer: R. G.Head Of Human Resources: D. S.Head Of Product: C. S.. Explore Kyo's employee directory with LeadIQ.

What industry does Kyo belong to?

Kyo operates in the Mental Health Care industry.

What technology does Kyo use?

Kyo's tech stack includes TikTok PixelFacebook PixelTableauApple iCloud MailLightboxMoment.jsGoogle SheetsPriority Hints.

What is Kyo's email format?

Kyo's email format typically follows the pattern of FLast@gatewaylg.com. Find more Kyo email formats with LeadIQ.

When was Kyo founded?

Kyo was founded in 2005.

Kyo

Q: What is Kyo's official website and social media links?

Kyo's official website is kyocare.com. Kyo has social profiles on LinkedIn.

Q: How many employees does Kyo have currently?

Kyo has approximately 1.1K employees.

Q: What technology does Kyo use?

Kyo's tech stack includes Ubuntu, PHP, Lightbox, WP Rocket, jsDelivr.

Mental Health CareCalifornia, United States1001-5000 Employees

At Kyo, we exist to help create a life that’s more fulfilling for our clients, for ourselves, and for each other. We thrive on big, extraordinary challenges where super ideas originate, and believe that scientific discovery needs empathy in order to be effective and influential. 

We are for the driven, open, and ambitious looking to make an impact in their community. We believe in making every minute count when we’re together, and will strive to help you do the same while we’re apart. Together, we will change what is possible for those with autism.

Company Overview

Headquarters: 295 89th St Suite 306 Daly City, California 94015 US
Phone number: +1-415-513-****
Website: kyocare.com
Stock Symbol: OKYO
NAICS Code: 62133 - Offices of Mental Health Practitioners (except Physicians)
Founded: 2005
Employees: 1001-5000

Media & News

Funding & Financials

$50M$100M
Kyo's revenue is estimated to be in the range of $50M$100M

Funding & Financials

$50M$100M
Kyo's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Kyo

Lightspeed

Infor

Revel Systems

Agilysys

Square

Toast

Kyo Tech Stack

Media & News

OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma to Present at OIS XV in San Diego

OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma reports company stock purchase by executive chair

OKYO Pharma maps out registration path with 100-patient trial of Urcosimod for neuropathic corneal pain

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI

Kyo's Email Address Formats

Frequently Asked Questions

Where is Kyo's headquarters located?

What is Kyo's phone number?

What is Kyo's stock symbol?

What is Kyo's official website and social media links?

What is Kyo's NAICS code?

How many employees does Kyo have currently?

What industry does Kyo belong to?

What technology does Kyo use?

What is Kyo's email format?

When was Kyo founded?

Kyo

Company Overview

Media & News

OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma to Present at OIS XV in San Diego

OKYO Pharma Announces Chairman and Founder Acquires Shares

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?